IMVT
Immunovant Inc.
$26.99
-$1.63(-5.70%)
43
Overall
50
Value
50
Tech
31
Quality
Market Cap
$5.40B
Volume
2.35M
52W Range
$13.36 - $30.09
Target Price
$40.29
Company Overview
| Mkt Cap | $5.40B | Price | $26.99 |
| Volume | 2.35M | Change | -5.70% |
| P/E Ratio | -13.1 | Open | $28.62 |
| Revenue | -- | Prev Close | $28.62 |
| Net Income | $-413.8M | 52W Range | $13.36 - $30.09 |
| Div Yield | N/A | Target | $40.29 |
| Overall | 43 | Value | 50 |
| Quality | 31 | Technical | 50 |
No chart data available
About Immunovant Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Sector: Industrials
Industry: Biological Product (except Diagnostic) Manufacturing
Latest News
Analysts’ Top Healthcare Picks: Sandoz Group Ltd (SDZXF), Immunovant (IMVT)
Howard Kim•a day ago
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
TipRanks Weekend Auto-Generated Newsdesk•4 days ago
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up
TipRanks Weekend Auto-Generated Newsdesk•18 days ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
Howard Kim•23 days ago
Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT)
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMVT | $26.99 | -5.7% | 2.35M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |